Regarding the IL-17A blockade, clinical trials have shown mostly modest effects in RA, especially compared with the clinical efficacy observed in psoriatic arthritis, psoriasis and spondyloarthritis (30). This evidence concerns the gene IL17A and spondyloarthropathy.